EW 财务： Edwards Lifesciences Corp AI 分析

Q: Edwards Lifesciences Corp 的关键财务报表是什么？

根据最新的财务报表（Form-10K），Edwards Lifesciences Corp 的总资产为 $13,055，净利润为 $4,174

Q: EW 的关键财务比率是什么？

Edwards Lifesciences Corp 的流动比率是 4.27，净利 margin 为 76.74，每股销售为 $9.07。

Q: Edwards Lifesciences Corp 的收入按细分市场或地理位置如何划分？

Edwards Lifesciences Corp 最大收入来源是 Transcatheter Aortic Valve Replacement，在最近的收益报告中收入为 4,106,100,000。就地区而言， United States 是 Edwards Lifesciences Corp 的主要市场，收入为 3,206,000,000。

Q: Edwards Lifesciences Corp 是否盈利？

是的，根据最新的财务报表，Edwards Lifesciences Corp 的净利润为 $4,174

Q: Edwards Lifesciences Corp 有负债吗？

是的，Edwards Lifesciences Corp 的负债为 3,056

Q: Edwards Lifesciences Corp 的流通股有多少？

Edwards Lifesciences Corp 的总流通股为 588.6

主页

股票

EW

EW 财务

Edwards Lifesciences Corp

$83.46

-1.05%

$-0.89

收盘价：Jan 20, 16:00:00 GMT-5

$84

0.64%

$0.54

盘前：Jan 21, 04:33:05 GMT-5

概述预测收益股息财务数据

360

报告

最终得分

关键数据

前收盘价

$84.35

开盘价

$83.72

当日区间

$82.82 - $85.16

52周范围

$65.94 - $87.89

交易量

3.2M

平均成交量

3.9M

每股收益（TTM）

2.33

股息收益率

市值

$48.7B

什么是 EW？

Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. The company is headquartered in Irvine, California and currently employs 15,800 full-time employees. The company went IPO on 2000-03-27. The firm partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. The company provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. The company is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.

功能特性

交易策略

资源

市场

收入

资产负债表

现金流量

年度

季度性

EW 收入

以百万美元为单位的财务数据。财年为2月至次年1月。

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
营收	5,883	5,439	5,010	4,464	5,232	4,386
营收同比增长 (YoY)	5%	9%	12%	-15%	19%	1%
营收成本	1,283	1,117	978	723	1,248	1,080
毛利润	4,600	4,322	4,031	3,740	3,983	3,305
销售、一般及管理费用	1,974	1,789	1,582	1,357	1,493	1,228
研发	1,082	1,053	962	843	903	760
营业费用	2,968	2,841	2,519	2,165	2,272	2,002
其他非经营性收入 (费用)	30	7	4	1	1	-1
税前利润	1,572	1,548	1,372	1,519	1,702	916
所得税费用	235	152	152	195	198	93
净利润	1,367	4,174	1,402	1,521	1,503	823
净利润增长	-67%	198%	-8%	1%	83%	-21%
稀释后流通股数	585.7	599.3	609.4	624.2	631.2	631.9
股份同比变动 (YoY)	-2%	-2%	-2%	-1%	0%	-1%
每股收益 (摊薄)	2.33	6.96	2.3	2.43	2.38	1.3
每股收益增长率	-66%	202.99%	-5%	2%	83%	-21%
自由现金流	799	259	629	953	1,402	647
每股自由现金流	--	--	--	--	--	--
毛利率	78.19%	79.46%	80.45%	83.78%	76.12%	75.35%
营业利润率	27.72%	27.21%	30.17%	35.25%	32.68%	29.7%
净利率	23.23%	76.74%	27.98%	34.07%	28.72%	18.76%
自由现金流利润率	13.58%	4.76%	12.55%	21.34%	26.79%	14.75%
EBITDA	1,787	1,635	1,656	1,713	1,844	1,410
EBITDA 利润率	30.37%	30.06%	33.05%	38.37%	35.24%	32.14%
EBITDA 中的折旧与摊销	156	155	144	139	134	107
EBIT	1,631	1,480	1,512	1,574	1,710	1,303
EBIT 利润率	27.72%	27.21%	30.17%	35.25%	32.68%	29.7%
有效税率	14.94%	9.81%	11.07%	12.83%	11.63%	10.15%

Follow-Up Questions

Edwards Lifesciences Corp 的关键财务报表是什么？



EW 的关键财务比率是什么？



Edwards Lifesciences Corp 的收入按细分市场或地理位置如何划分？



Edwards Lifesciences Corp 是否盈利？



Edwards Lifesciences Corp 有负债吗？



Edwards Lifesciences Corp 的流通股有多少？



Edwards Lifesciences Corp（EW）价格

EW 股价走势图